Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.6B |
| 2 |
Broadcom
AVGO
|
+$1.11B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$882M |
| 4 |
JPMorgan Chase
JPM
|
+$628M |
| 5 |
Tesla
TSLA
|
+$594M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.54B |
| 2 |
Visa
V
|
+$1.39B |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.13B |
| 4 |
Amazon
AMZN
|
+$771M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$575M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.83% |
| 2 | Financials | 7.37% |
| 3 | Consumer Discretionary | 6.6% |
| 4 | Communication Services | 5.05% |
| 5 | Healthcare | 4.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4101
State Street SPDR S&P Aerospace & Defense ETF
XAR
$6.62B
| $229K | ﹤0.01% |
1,085
+125
| +13% | +$22.7K |
|
|
ACTU
4102
Actuate Therapeutics
ACTU
$23.7M
| $228K | ﹤0.01% |
+37,334
| New | +$326K |
|
4103
Dynagas LNG Partners
DLNG
$136M
| $228K | ﹤0.01% |
64,800
| – | – |
|
4104
Ohio Valley Banc Corp
OVBC
$209M
| $227K | ﹤0.01% |
+7,041
| New | +$234K |
|
4105
BK Technologies
BKTI
$287M
| $226K | ﹤0.01% |
4,802
+4,717
| +5,549% | +$211K |
|
|
VTYX
4106
DELISTED
Ventyx Biosciences
VTYX
| $226K | ﹤0.01% |
105,397
+44,034
| +72% | +$71.1K |
|
|
CIRC
4107
Circle8 Group
CIRC
$63.9M
| $225K | ﹤0.01% |
+110,899
| New | +$334K |
|
4108
CALL
Teladoc Health
TDOC
$1.21B
| $224K | ﹤0.01% |
25,700
| – | – |
|
4109
Eastern Company
EML
$161M
| $223K | ﹤0.01% |
9,784
+4,537
| +86% | +$102K |
|
4110
ECB Bancorp
ECBK
$175M
| $223K | ﹤0.01% |
14,455
+14,399
| +25,713% | +$226K |
|
4111
InMode
INMD
$871M
| $223K | ﹤0.01% |
15,449
-99,938
| -87% | -$1.47M |
|
4112
Aclaris Therapeutics
ACRS
$868M
| $222K | ﹤0.01% |
156,337
+37,336
| +31% | +$50.5K |
|
4113
Comp X International
CIX
$395M
| $222K | ﹤0.01% |
8,347
+1,158
| +16% | +$28.6K |
|
4114
Lifeway Foods
LWAY
$452M
| $221K | ﹤0.01% |
8,978
+4,089
| +84% | +$96.9K |
|
4115
Tucows
TCX
$145M
| $221K | ﹤0.01% |
11,223
+2,547
| +29% | +$45.6K |
|
4116
Neuronetics
STIM
$216M
| $221K | ﹤0.01% |
+63,380
| New | +$250K |
|
4117
Maui Land & Pineapple Co
MLP
$322M
| $221K | ﹤0.01% |
12,143
+3,915
| +48% | +$63.5K |
|
4118
LENSAR
LNSR
$74.5M
| $221K | ﹤0.01% |
+16,770
| New | +$226K |
|
4119
FT Vest US Equity Enhance & Moderate Buffer ETF March
XMAR
$154M
| $221K | ﹤0.01% |
5,765
+1,775
| +44% | +$65.7K |
|
|
RDFN
4120
DELISTED
Redfin
RDFN
| $220K | ﹤0.01% |
19,654
-511,699
| -96% | -$5.02M |
|
|
DRUG
4121
Bright Minds Biosciences
DRUG
$775M
| $219K | ﹤0.01% |
+8,393
| New | +$252K |
|
4122
Motley Fool 100 Index ETF
TMFC
$2.12B
| $218K | ﹤0.01% |
3,387
| – | – |
|
|
CVAC
4123
DELISTED
CureVac
CVAC
| $218K | ﹤0.01% |
40,193
+1,949
| +5% | +$7.73K |
|
4124
Landmark Bancorp
LARK
$197M
| $218K | ﹤0.01% |
+8,646
| New | +$231K |
|
4125
Coherus Oncology
CHRS
$190M
| $218K | ﹤0.01% |
297,692
+66,702
| +29% | +$57.6K |
|
Similar funds
Barclays's Q2 2025 Portfolio in Review
As of Q2 2025, Barclays held 5,681 positions worth $436B, up 24% from $353B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Barclays deployed $35.4B of net new capital in Q2 2025, opening 461 new positions and adding to 2,914 existing holdings. Its largest new stake was iShares MBS ETF: 4,310,047 shares worth $405M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 18% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Honeywell, an estimated $1.54B trimmed.
- Barclays's largest Q2 2025 buy was iShares MBS ETF: 4,310,047 shares worth $405M.
- Barclays added most to NVIDIA in Q2 2025, an estimated $1.6B increase.
- Barclays's biggest Q2 2025 reduction was Honeywell, cutting an estimated $1.54B.
- Barclays fully exited Berry Global Group, Inc. in Q2 2025, selling an estimated $173M.
- Barclays's ten largest holdings make up 43% of its $436B portfolio in Q2 2025.
- Barclays opened 461 new positions and closed 463 in Q2 2025.
- Barclays's portfolio value rose 24% quarter-over-quarter to $436B.
Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.